BioLargo (BLGO) AI Stock Analysis

• Market Cap: $53.08M
• Dividend Yield: N/A
• Average Volume (3M): 475.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.37
• Revenue Growth: -16.42%
• EPS Growth: -34.38%
• Country: US
• Employees: 40
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): >-0.01
• Shares Outstanding: 308,989,040
• 10 Day Avg. Volume: 682,373
• 30 Day Avg. Volume: 475,767
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 4.26
• Enterprise Value/Gross Profit: 9.38
• Enterprise Value/Ebitda: -9.79
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

BioLargo's overall stock score is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates bearish momentum, and the valuation is unattractive due to negative earnings. These factors collectively result in a low overall score.

BioLargo Business Overview & Revenue Model

Company Description

BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

How the Company Makes Money

BioLargo generates revenue through multiple streams, primarily by selling its proprietary technologies and products to commercial and industrial clients. The company earns income from product sales, licensing its technologies, and providing consulting services related to environmental solutions. Additionally, BioLargo has established strategic partnerships with municipalities and industries that rely on its advanced treatment solutions, which further contribute to its revenue. The company also explores opportunities for government grants and funding related to environmental initiatives, enhancing its earnings potential.

BioLargo Financial Statement Overview

Summary

BioLargo shows strong revenue growth, indicating market acceptance and expansion potential. However, persistent profitability and cash flow challenges highlight the need for operational improvements and strategic financial management to achieve sustainable profitability and liquidity.

Income Statement

BioLargo has demonstrated significant revenue growth, increasing from $1.86M in 2019 to $17.78M in 2024, showing a strong upward trajectory. However, the company remains unprofitable with consistent net losses, including a net loss of $2.40M in 2024. The gross profit margin has improved but remains volatile. EBIT and EBITDA margins remain negative, indicating operational challenges.

Balance Sheet

BioLargo's financial stability is supported by a strong equity position with a debt-to-equity ratio significantly improved over the years, now at 0.17. The equity ratio is healthy at 84.18%. However, the company has high leverage in earlier years and a history of negative net debt, indicating potential liquidity risks.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing operational cash burn. Free cash flow growth has not been positive, and the free cash flow to net income ratio remains challenging. While financing activities have supported cash needs, sustained negative cash flows pose a risk to long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.05M	17.78M	12.23M	5.88M	2.53M	2.43M
Gross Profit	6.38M	7.85M	6.15M	2.86M	1.10M	1.23M
EBITDA	-6.11M	-4.06M	-4.19M	-5.10M	-6.70M	-7.83M
Net Income	-3.90M	-2.40M	-3.50M	-4.50M	-7.38M	-10.47M
Balance Sheet
Total Assets	12.50M	10.51M	8.21M	4.86M	3.02M	4.94M
Cash, Cash Equivalents and Short-Term Investments	3.47M	3.55M	3.54M	1.85M	962.00K	716.00K
Total Debt	3.67M	2.55M	1.70M	1.47M	1.13M	2.67M
Total Liabilities	6.44M	4.46M	4.00M	2.85M	2.09M	5.18M
Stockholders Equity	8.76M	8.85M	6.84M	4.88M	4.65M	3.86M
Cash Flow
Free Cash Flow	-7.50M	-4.44M	-2.84M	-3.03M	-3.97M	-4.18M
Operating Cash Flow	-7.48M	-3.21M	-2.37M	-2.76M	-3.94M	-4.15M
Investing Cash Flow	96.00K	-1.32M	-478.00K	-271.00K	-34.00K	-123.00K
Financing Cash Flow	6.05M	4.44M	4.66M	3.96M	4.23M	4.34M

BioLargo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.19, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 33.80 is Neutral, neither overbought nor oversold. The STOCH value of 42.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.

BioLargo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	67 Neutral	$446.89M	4.59	9.65%	2.03%	4.04%	283.22%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
LXU	59 Neutral	$646.71M	―	-6.51%	―	2.60%	-1506.69%
FF	54 Neutral	$172.58M	11.43	-13.48%	6.09%	-51.14%	-165.98%
RYAM	50 Neutral	$505.86M	―	-81.36%	―	-4.90%	-458.80%
ORGN	42 Neutral	$79.45M	―	-25.50%	―	-15.84%	-605.38%
BLGO	41 Neutral	$53.08M	―	-52.83%	―	-16.42%	-34.38%

BioLargo Corporate Events

BioLargo Hosts Webcast Investor Conference Presentation

BioLargo, Inc. participated in a webcast investor conference on August 15, 2025, where they presented a slide show. The information shared during this event is not considered filed with the SEC and is not subject to certain liabilities under the Securities Exchange Act of 1934 or the Securities Act of 1933.

BioLargo Highlights 2025 Progress and Future Outlook

On July 23, 2025, BioLargo, Inc. provided a mid-year review of its 2025 accomplishments and future outlook. The company highlighted the progress of its subsidiary, Clyra Medical, which is entering the next stage of commercialization with its infection control and wound care products, now available in numerous U.S. healthcare facilities. Additionally, BioLargo’s Cellinity battery technology is gaining traction globally, with a unique ‘sell factories, not batteries’ business model that aims to address the demand for long-duration energy storage. The company has signed several MOUs with prospective partners to build battery factories, indicating a promising financial upside.

BioLargo Approves Proposals at Annual Meeting

At its 2025 annual stockholder meeting on June 19, 2025, BioLargo, Inc. announced the approval of all proposals, including the election of board members and the authorization for a potential reverse stock split. Although the reverse stock split was approved, the board has no immediate plans to implement it, intending to do so only if necessary for uplisting to a national exchange. CEO Dennis Calvert highlighted the company’s strategic positioning and readiness to expand its market reach and attract institutional investors when conditions are favorable.